JPRN-jRCT2080225293已完成1 期
An Open-label Study to Assess the Safety and Tolerability of a Single Dose of S-600918 (Part 1) and a Randomized, Double-blind, Placebo- and Positive-controlled, 4-Period Crossover, Thorough QT/QTc Study of S-600918 (Part 2) in Healthy Adult Participants
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 55age old（—）
- 性别
- All
入选标准
- •Healthy subjects
排除标准
- •Subjects who are considered ineligible for this study by the investigator or subinvestigator due to current or history of significant metabolic or endocrine, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, immune, neurological or psychiatric disorders, or other clinically significant diseases.
研究者
相似试验
进行中（未招募）
2 期
An Open Label Study Assessing the Safety and Tolerability of SB206 in Japanese subjects with Molluscum ContagiosumMolluscum contagiosumJPRN-jRCT2031230123Yoshiyuki Kaneko20
进行中（未招募）
不适用
Open-Label Safety Study of MF/F in AsthmaPersistent AsthmaEUCTR2014-004583-38-Outside-EU/EEASchering-Plough Research Institute, a division of Schering Corporation49
已完成
1 期
An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Dapagliflozin 70 mg Extended Release Capsules in Healthy VolunteersType 2 Diabetes MellitusACTRN12620001187932ovotech (Australia) Pty Limited10
终止
1 期
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Dapagliflozin Extended Release Capsules in Healthy Volunteers.ACTRN12619001577101yndra Australia Pty Ltd44
已完成
1 期
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Rosuvastatin Extended Release CapsulesdyslipidemiaACTRN12621000101886yndra Therapeutics, Inc. (Lyndra)16